- Reference code :
- wf463
- Published date :
-
12 December 2002
- Expired date :
-
29 April 2030
AstraZeneca today announced that the High Court of Australia has granted its appeal against an earlier Federal Court decision in a dispute with the generic pharmaceutical company, Alphapharm Pty Limited, about the validity of the formulation patent for omeprazole – the active substance used in Losec, a treatment for acid-related disorders, such as peptic ulcers.
The High Court overturned a decision in October, 2000, by the Full Federal Court of Australia, declaring the patent invalid due to obviousness. The latest judgment restores the patent’s validity and agrees with AstraZeneca’s argument that the patent is not obvious and involves inventive step.
The proceedings will now return to the lower courts for disposal of remaining issues.
Australia represented about 2 per cent of Losec worldwide sales in 2001.
Further enquires to:
Media EnquiriesSteve Brown +44 (0)20 7304 5033 |
Investor RelationsMina Blair-Robinson +44 (0)20 7304 5084 Jonathan Hunt +44 (0)20 7304 5087 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:30 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
